34 results on '"Bellone, M."'
Search Results
2. EE448 The Economic Impact of Polatuzumab Vedotin as First-Line Therapy for High-Risk DLBCL on Subsequent Treatments Within the Italian National Health Service
3. CO146 Systematic Literature Review of Hospital Time and Resource Consumption in Subcutaneous and Intravenous Oncologic Biologic Therapies: The Case Study of Atezolizumab From an Italian Perspective
4. EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy
5. Étude des troubles psychiatriques et des modalités défensives évaluées par le « Defense Style Questionnaire » (DSQ) dans un échantillon d’hommes stériles consultant en andrologie
6. EE223 Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients With Advanced Follicular Lymphoma: A Cost Analysis
7. EE115 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin With Rituximab and Chemotherapy vs Rituximab and Chemotherapy in Treating Naïve Diffuse Large B-Cell Lymphoma in Italy
8. EE107 Ponesimod Indicated for Patients With Active Relapsing Forms of Multiple Sclerosis: A Budget Impact Analysis From the Italian National and Regional Health Care Service Perspective
9. POSC113 Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer (HER2+ BC) Patients in Italy: A Budget Impact Analysis
10. POSB109 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin with Bendamustine and Rituximab vs. Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
11. POSB108 Cost-Effectiveness and Cost-Utility Analyses of Atezolizumab-Based Therapy in Patients with Advanced or Unresectable Hepatocellular Carcinoma in Italy
12. POSA108 A Budget Impact Analysis of Atezolizumab Monotherapy for First Line Treatment of Patients with PD-L1 High Metastatic NSCLC in Italy
13. PCN85 An Updated Cost-Utility Analysis in Italian Patients of Entrectinib Compared to Standard of Care in NTRK+ Tumor Agnostic Indication
14. PCN66 Cost-Effectiveness Model Adapted to Italian Clinical Practice for Evaluation of Entrectinib Versus Crizotinib in ROS1+ NSCLC Patients
15. PCN156 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
16. PCN152 COST-UTILITY AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE FOR EVALUATION OF ENTRECTINIB VERSUS STANDARD OF CARE IN ROS1+ NSCLC PATIENTS
17. PCN148 COST-UTILITY OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1+ NSCLC PATIENTS: AN AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE
18. PCN147 ENTRECTINIB IN NTRK TUMOR AGNOSTIC INDICATION COMPARED TO DIFFERENT STANDARD OF CARE IN VARIOUS TUMORS TYPES: A COST-EFFECTIVENESS ANALYSIS IN ITALIAN PATIENTS
19. SC315 - Development and validation of a novel EPS-metabolomic signature for the diagnosis of clinically significant prostate cancer
20. 852 - Iron induces ferroptosis and synergizes with anti-androgen therapy in prostate cancer pre-clinical models
21. PSY108 - COST-UTILITY ANALYSIS OF TOCILIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF GIANT CELL ARTERITIS IN ITALIAN PATIENTS
22. PSY44 - TOCILIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF GIANT CELL ARTERITIS: A BUDGET IMPACT ANALYSIS IN ITALY
23. PMU41 - PAST, CURRENT AND EXPECTED NEED FOR HOME ARTIFICIAL NUTRITION IN PIEDMONT: RESOURCES NEEDED TO MAINTAIN A RECOGNIZED HIGH QUALITY LEVEL
24. PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTS
25. PCN82 - BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
26. OR16: Pharmacoeconomic Analysis of Structured Triglycerides in Critically ILL Chinese Patients
27. EP-2053: In-vivo imaging of rat leukocytes redistribution after pelvic irradiation
28. PCV88 - Cost Effectiveness Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
29. PCV83 - Pharmacoeconomic Assessment Of Apixaban Versus Standard Of Care For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
30. PCV39 - Budget Impact Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
31. Systems biology assessment of binary mixture effects in the social amoeba Dictyostelium discoideum
32. PND95 - Development of Ms Budget Manager: A Practical Tool to Assist Alternative Stakeholders At Multiple Decision Levels In The Forecast And Financial Management For Multiple Sclerosis (Ms)
33. PCN139 - Cost-Effectiveness Analysis Of Neo-Adjuvant Pertuzumab Therapy In Women With Locally Advanced, Inflammatory, Or Early Her2-Positive Breast Cancer In Italy
34. ISPM: A DSS for personnel career management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.